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DNA damage and human chromosome instability syn- in cancer trickled out (actually a relatively short period
in the timeframe of translating a new concept to actualdromes, are informative and well balanced between
clinical development). In this first decade, antigen tar-facts and models. The latter two chapters also point to
gets on cancer cells had to be identified and sufficientimportant future directions of DNA repair research: the
quantities of clinical grade antibodies needed to be pro-connections among DNA damage, repair intermediates,
duced, accomplished largely in these early years in aca-and signaling and execution of DNA damage check-
demic laboratories with relatively small budgets. Aspoints.
sometimes happens with new cancer therapies, initialThese books should be of value to anyone interested
clinical trials fueled optimism when objective tumor re-in DNA repair. They are written so as to be accessible
gressions were observed in selected patients with lym-to molecular biologists and cancer researchers ranging
phoma (Miller, 1982) and solid tumors (Houghton, 1985).from enzymologists to oncogene and tumor suppressor
However substantial problems were also identifiedhunters, to clinical oncologists. Naturally, all DNA repair
(Scheinberg and Houghton, 1987). These included, amongresearchers, whether they are first-year graduate stu-
others: (1) immunogenicity of mAbs, leading to resis-dents or professors, may greatly benefit from this book.
tance and rapid clearance of antibodies from the body;I recommend the book highly and congratulate the edi-
(2) difficulties of targeting antibodies, which are fairlytors and authors for a job well done.
large protein molecules, into tissues especially into solid
tumors; (3) a perceived need to increase potency ofAziz Sancar
tumor destruction by conjugating nuclides, toxins, andDepartment of Biochemistry and Biophysics
other virulent molecules to mAbs; and (4) the increas-University of North Carolina School of Medicine
ingly high cost of producing clinical grade mAbs. A newChapel Hill, North Carolina 27599
jargon emerged among the cognicenti in the mAb field,
including RIT (radioimmunotherapy), HAMA (human
anti-mouse antibodies), HARA (human anti-ricin anti-
bodies), and the laughable term HAHA (human anti-
Raising Monoclonal Antibodies humanized antibody).
In this first decade, enthusiasm and expectations
were high, energized further by preliminary results withMonoclonal Antibody±Based Therapy of Cancer
other biologic agents including interleukin-2, erythropoi-Edited by Michael L. Grossbard
etin, and granulocyte colony±stimulating factor. How-New York: Marcel Dekker (1998). 464 pp. $185.00
ever the problems identified in the early clinical trials
were substantial and stalled further clinical developmentWhile growing up, my father constantly reminded me
into the 1990s. These teen years were difficult: the reac-that patience was a virtue. He was presumably reacting
tion from the medical community, pharmaceutical indus-to the impetuous nature of children. These childhood
try, and public was swift and stern. The lack of rapidtraits often serve scientists well, driving creativity and
advancement of early phase I clinical trials to phase IIIpushing new frontiers. However, translating new discov-
trials (where efficacy of treatments is established in or-eries to improve the human condition is a different kettle
der to obtain approval to market a new treatment) was
of fish, rarely leading to instant gratification. More often
interpreted as failure. In particular, quantities of mAb
than not, clinical research requires persistence, durabil-
were limited, frustrating more incisive clinical trials.
ity, and some luck. However, the problems that were identified also had
Monoclonal antibodies (mAbs) burst onto the scene potential solutions. The problems of immunogenicity
in 1975 with the report by Kohler and Milstein (1975) could be overcome at least partially by engineering ªhu-
that somatic cell hybridization could be used to rescue manizedº mAbs. Penetration into solid tumors might
and immortalize B cells secreting immunoglobulins of be improved by miniaturizing the antibody. An array of
defined specificities. The implications were quickly rec- nuclides, drugs, and toxins appeared that might in-
ognized. Many variations on this general theme fol- crease potency. It was too early to declare the demise of
lowed, such as phage displays and engineering better mAbs for the treatment of cancer. Further development
antigen-binding sites. The application of mAbs as re- required substantial resources, which were provided by
agents in experimental laboratories steadily emerged several perceptive biotechnology and pharmaceutical
over several decades, now typically consuming increas- companies.
ing proportions of laboratory budgets. By the mid-1990s, mAbs were quietly moving out of
In the early, heady days after the original Kohler and their adolescent identity crisis to become real treat-
Milstein report, it was hoped that mAbs would quickly ments. In cancer therapy, reports of clinical responses
emerge as treatments for diseases. This hope was par- after mAb treatments in patients with lymphoma became
ticularly attractive for cancer where new therapies are more frequent. One mAb, Rituxan, directed against the
meager and ªsuccessfulº new treatments usually involve CD20 B cell differentiation antigen (McLaughlin, 1998)
small increments in efficacy. Here was a way to poten- was approved in 1997 by the FDA for treatment of pa-
tially target molecules on cancer cells, using mAbs as tients with relapsed or refractory low2grade or follicular
ªsilver bullets,º ªguided missiles,º or my personal favor- B cell lymphomas, and other mAb-based treatments for
ite ªtumor-seeking A bomb.º Perhaps this would open lymphoma may follow shortly. In 1998, the FDA ap-
an era of rationally designed, targeted therapies against proved Herceptin, an mAb directed against the HER2/
cancer. neu surface protein overexpressed on metastatic can-
However, it took 5±10 years after the Kohler and cers in 25%±30% of women with breast carcinoma. Her-
ceptin improved response rates in combination with theMilstein report before the results of the first clinical trials
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chemotherapy agent paclitaxel and could induce tumor is that mAbs can also work by binding to cell surface
molecules that are involved in life, death, and growthregressions in women with metastatic breast cancer
who had failed first-line therapies. A wise clinical investi- decisions of cancer cells. Molecules such as CD20 and
HER2/neu provide signals for growth and survival ofgator told me 15 years ago that mAbs would fit best
when combined with chemotherapy (prescient remarks cancer cells, and altering these signals may be neces-
sary for clinical efficacy of the respective mAbs. It will beconsidering the Herceptin story). Treatment of high-risk
patients with colorectal carcinoma using the mAb 17-1A important to sort out immune and inflammatory effects
versus direct biologic effects on receptors, especiallyas an adjuvant treatment has shown improved survival in
one randomized study (Riethmuller, 1998), and these as we add on cytotoxic molecules such as nuclides or
results are being tested in a follow-up clinical trial. In toxins. But this is when clinical research is at its best.
noncancer diseases, mAbs were being approved for Clinical observations are wonderful phenomena that
inhibiting transplantation rejection, decreasing risk of form the basis for addressing scientific questions. And
myocardial infarction and death after balloon angio- what could be a better question than how mAbs cause
plasty, and treatment of inflammatory bowel disease tumors to regress or disappear in people.
(with possible application to other inflammatory dis-
eases like rheumatoid arthritis). Things were definitely
looking up. Alan N. Houghton
The volume Monoclonal Antibody-Based Therapy of Memorial Sloan-Kettering Cancer Center
Cancer, edited by Michael L. Grossbard, provides a use- New York, New York 10021
ful snapshot of mAbs for cancer treatment in the late
1990s, reflecting cautious optimism and in some cases
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